Occurrence of epidermal growth factor receptors in benign and malignant ovarian tumors and normal ovarian tissues: an immunohistochemical study.

Henzen-Logmans SC, van der Burg ME, Foekens JA, Berns PM, Brussée R, Fieret JH, Klijn JG, Chadha S, Rodenburg CJ
Journal of cancer research and clinical oncology · 1992 · doi:10.1007/bf01208620 · PMID:1315781 · PMC12200527
OA: closed
📄 Open PDF Full text JSON View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-08-27 ⓘ

This immunohistochemical study of ovarian tumors and normal tissues found enhanced epidermal growth factor receptor expression in 52% of cases, with staining also present in stromal, endothelial, and necrotic areas.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-27 · read from full text ⓘ

This immunohistochemical study analyzed epidermal growth factor receptor (EGF-R) expression in 50 ovarian tumors and 10 normal ovarian tissues using monoclonal antibody 2E9. The researchers found enhanced EGF-R expression in 52% of the tumors, with staining localized to the cytoplasm of epithelial, stromal, and endothelial cells, as well as necrotic areas. Notably, no correlation existed between EGF-R levels and the histological type of epithelial tumor, while low immunoreactivity was also present in non-tumorous tissue components. These findings highlight potential confounding factors for biochemical binding studies that do not account for stromal or necrotic staining patterns. Relevance to endometriosis: listed as one indication for GnRH antagonists, though the paper's main focus is uterine fibroids.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Epidermal growth factor receptor (EGF-R) was studied with monoclonal antibody 2E9 on 50 ovarian tumors of various histological types and 10 non-tumorous ovarian tissues by immunohistochemistry. Enhanced expression was observed in 26/50 (52%) of the tumors. Only 25 out of 46 epithelial tumors (54%) showed positivity in epithelial tumor cells. Staining was cytoplasmic in all cases. No correlation was established between EGF-R expression and the histological type of the epithelial tumor. Apart from EGF-R expression in tumor cells, low immunoreactivity was also observed in stromal and endothelial cells in both normal and tumorous ovarian tissues. Furthermore in 8/9 specimens containing necrotic areas, EGF-R was noticed in these areas as well. Both of the latter observations may have impact on the evaluation of the prognostic value of EGF-R activity in tumors, when based on EGF-R measurements using biochemical binding studies. We therefore recommend that EGF-R is measured with both methods in studies regarding its clinical value.
Full text 1,889 characters · extracted from oa-html · click to expand
1992-04-01 Occurrence of epidermal growth factor receptors in benign and malignant ovarian tumors and normal ovarian tissues: an immunohistochemical study Publication Publication Journal of Cancer Research and Clinical Oncology , Volume 118 - Issue 4 p. 303- 307 Epidermal growth factor receptor (EGF-R) was studied with monoclonal antibody 2E9 on 50 ovarian tumors of various histological types and 10 non-tumorous ovarian tissues by immunohistochemistry. Enhanced expression was observed in 26/50 (52%) of the tumors. Only 25 out of 46 epithelial tumors (54%) showed positivity in epithelial tumor cells. Staining was cytoplasmic in all cases. No correlation was established between EGF-R expression and the histological type of the epithelial tumor. Apart from EGF-R expression in tumor cells, low immunoreactivity was also observed in stromal and endothelial cells in both normal and tumorous ovarian tissues. Furthermore in 8/9 specimens containing necrotic areas, EGF-R was noticed in these areas as well. Both of the latter observations may have impact on the evaluation of the prognostic value of EGF-R activity in tumors, when based on EGF-R measurements using biochemical binding studies. We therefore recommend that EGF-R is measured with both methods in studies regarding its clinical value. | Additional Metadata | | |---|---| | , , | | | doi.org/10.1007/BF01208620, hdl.handle.net/1765/62105 | | | Journal of Cancer Research and Clinical Oncology | | | Organisation | Department of Pathology | | Henzen-Logmans, S., van der Burg, M., Foekens, J., Berns, E., Brussée, R., Fieret, J., Klijn, J., Chadha, D.& Rodenburg, C. (1992). Occurrence of epidermal growth factor receptors in benign and malignant ovarian tumors and normal ovarian tissues: an immunohistochemical study. Journal of Cancer Research and Clinical Oncology, 118(4), 303–307.https://doi.org/10.1007/BF01208620 |

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-10-04T09:26:46.659050+00:00
unpaywall
last seen: 2026-10-05T06:32:29.880811+00:00